- In the first six months of 2020, HARTMANN achieved organic sales growth of 16 % and a significant improvement in earnings
- The forecast is raised due to the ongoing compensation of lower profitability in the Wound Management segment through increased sales of disinfectants and personal protective equipment; the extent of temporary overcompensation exceeds expectations
- Continued implementation of the Transformation Program to strengthen competitiveness in the face of growing price pressure in the healthcare sector due to the coronavirus pandemic
The coronavirus pandemic continued to dominate the second quarter of 2020. “During the coronavirus pandemic, the HARTMANN GROUP has lived up to its important responsibility as a company in the healthcare sector. In particular, we have largely been able to meet the increased demand for disinfectants and personal protective equipment, by making appropriate use of resources to increase production and expand sources of supply for individual product groups,” says Britta Fünfstück, CEO of the HARTMANN GROUP. In the first half of 2020, HARTMANN achieved a strong organic sales growth of 16 % and a significant increase in earnings. Britta Fünfstück adds, “The use of our products to handle the coronavirus pandemic led to a high demand in the Infection Management segment, which in 2020 will compensate for other business segments that have declined due to the pandemic. This effect occurred as expected, but, contrary to expectations, to a greater extent. With regards to the year 2020 as a whole, we therefore expect that the negative effects mentioned above will be more than offset by the positive development in the first half of the year.